This trial evaluates the feasibility of using lipid microspheres with ultrasound sonication (sonobiopsy) for the diagnosis of glioblastoma. Sonobiopsy disrupts the blood-brain barrier, enhancing the release of tumor biomarkers into blood circulation and allowing for noninvasive diagnosis and characterization of brain tumors. This study compares this technique with traditional tissue biopsy.
Additional locations may be listed on ClinicalTrials.gov for NCT05281731.
Locations matching your search criteria
United States
Missouri
Saint Louis
Siteman Cancer Center at Washington UniversityStatus: Active
Contact: Albert Kim
Phone: 314-747-6561
PRIMARY OBJECTIVES:
I. Determine the feasibility of sonobiopsy.
II. Evaluate the concordance of sonobiopsy and tissue biopsy.
OUTLINE:
Patients receive perflutren lipid microspheres intravenously (IV) over 30-60 seconds and then undergo ultrasound sonication. Patients then undergo planned surgery. Patients also undergo collection of blood samples at baseline, 10 minutes after sonication, and 30 and 60 minutes after sonication (optional). Patients undergo collection of tissue samples during standard of care surgery. Patients also undergo magnetic resonance imaging (MRI) post-sonication, immediately prior to standard of care surgery.
Trial PhaseNo phase specified
Trial Typediagnostic
Lead OrganizationSiteman Cancer Center at Washington University
Principal InvestigatorAlbert Kim